IL319342A - Co-crystals of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxyethoxy]pyrazolo[1,5-A]pyridin-6-yl]-5-methyl-triazol-1-yl]piperidine-1-caridine-1-caridine and nicotinamide - Google Patents
Co-crystals of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxyethoxy]pyrazolo[1,5-A]pyridin-6-yl]-5-methyl-triazol-1-yl]piperidine-1-caridine-1-caridine and nicotinamideInfo
- Publication number
- IL319342A IL319342A IL319342A IL31934225A IL319342A IL 319342 A IL319342 A IL 319342A IL 319342 A IL319342 A IL 319342A IL 31934225 A IL31934225 A IL 31934225A IL 319342 A IL319342 A IL 319342A
- Authority
- IL
- Israel
- Prior art keywords
- cancer
- cocrystalline form
- cocrystalline
- urothelial
- bladder cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
- C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263404232P | 2022-09-07 | 2022-09-07 | |
| PCT/US2023/073508 WO2024054814A1 (en) | 2022-09-07 | 2023-09-06 | Co-crystals of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxy-ethoxy]pyrazolo[1,5-a]pyridin-6-yl]-5-methyl- triazol-1-yl]piperidine-1 -carbonitrile derivatives with gallic acid and nicotine amide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL319342A true IL319342A (en) | 2025-05-01 |
Family
ID=88204177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL319342A IL319342A (en) | 2022-09-07 | 2023-09-06 | Co-crystals of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxyethoxy]pyrazolo[1,5-A]pyridin-6-yl]-5-methyl-triazol-1-yl]piperidine-1-caridine-1-caridine and nicotinamide |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240116932A1 (enExample) |
| EP (1) | EP4584270A1 (enExample) |
| JP (2) | JP7541606B2 (enExample) |
| KR (1) | KR20250057022A (enExample) |
| CN (1) | CN120187720A (enExample) |
| AR (1) | AR130417A1 (enExample) |
| AU (1) | AU2023338199A1 (enExample) |
| CA (1) | CA3266872A1 (enExample) |
| CL (1) | CL2025000596A1 (enExample) |
| CO (1) | CO2025002467A2 (enExample) |
| CR (1) | CR20250077A (enExample) |
| DO (1) | DOP2025000054A (enExample) |
| IL (1) | IL319342A (enExample) |
| PE (1) | PE20251400A1 (enExample) |
| TW (1) | TWI862146B (enExample) |
| WO (1) | WO2024054814A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025259519A1 (en) | 2024-06-13 | 2025-12-18 | Eli Lilly And Company | Activation of egfr/her2/3 in cancer after treatment with an inhibitor of fibroblast growth factor receptor 3 (fgfr3) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007067727A2 (en) | 2005-12-08 | 2007-06-14 | Ssci, Inc. | Metronidazole cocrystals and imipramine cocrystals |
| PH12012000132A1 (en) | 2011-06-09 | 2014-10-20 | Servier Lab | New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them |
| CN102964384B (zh) | 2012-11-09 | 2015-06-24 | 中山大学 | 阿德福韦酯没食子酸共晶及其制备方法和组合物 |
| JP2021523876A (ja) | 2018-02-13 | 2021-09-09 | トランスジェネックス ナノバイオテック、インコーポレイテッド | 癌治療のためのタミバロテンの新規の結晶形態 |
| US12180207B2 (en) * | 2018-12-19 | 2024-12-31 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases |
| CN111574359A (zh) | 2019-02-19 | 2020-08-25 | 愈磐生物科技（苏州）有限公司 | 乐伐替尼-没食子酸共晶晶型及其应用 |
| CN113943284B (zh) | 2020-07-15 | 2023-12-19 | 中国医学科学院药物研究所 | 盐酸吡格列酮没食子酸共晶及制备方法和其组合物与用途 |
| TW202402754A (zh) | 2021-03-04 | 2024-01-16 | 美商美國禮來大藥廠 | Fgfr3抑制劑化合物 |
-
2023
- 2023-09-06 CN CN202380077374.0A patent/CN120187720A/zh active Pending
- 2023-09-06 CR CR20250077A patent/CR20250077A/es unknown
- 2023-09-06 KR KR1020257010708A patent/KR20250057022A/ko not_active Ceased
- 2023-09-06 PE PE2025000482A patent/PE20251400A1/es unknown
- 2023-09-06 US US18/462,286 patent/US20240116932A1/en active Pending
- 2023-09-06 IL IL319342A patent/IL319342A/en unknown
- 2023-09-06 CA CA3266872A patent/CA3266872A1/en active Pending
- 2023-09-06 AU AU2023338199A patent/AU2023338199A1/en active Pending
- 2023-09-06 EP EP23777475.7A patent/EP4584270A1/en active Pending
- 2023-09-06 WO PCT/US2023/073508 patent/WO2024054814A1/en not_active Ceased
- 2023-09-07 JP JP2023145013A patent/JP7541606B2/ja active Active
- 2023-09-07 TW TW112133993A patent/TWI862146B/zh active
- 2023-09-07 AR ARP230102376A patent/AR130417A1/es unknown
-
2024
- 2024-08-16 JP JP2024136962A patent/JP2024153948A/ja active Pending
-
2025
- 2025-02-28 CO CONC2025/0002467A patent/CO2025002467A2/es unknown
- 2025-03-04 CL CL2025000596A patent/CL2025000596A1/es unknown
- 2025-03-06 DO DO2025000054A patent/DOP2025000054A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2025000054A (es) | 2025-03-31 |
| CR20250077A (es) | 2025-04-02 |
| TW202428260A (zh) | 2024-07-16 |
| TWI862146B (zh) | 2024-11-11 |
| CN120187720A (zh) | 2025-06-20 |
| CL2025000596A1 (es) | 2025-04-25 |
| CO2025002467A2 (es) | 2025-03-17 |
| PE20251400A1 (es) | 2025-05-22 |
| JP2024037713A (ja) | 2024-03-19 |
| JP2024153948A (ja) | 2024-10-29 |
| JP7541606B2 (ja) | 2024-08-28 |
| WO2024054814A1 (en) | 2024-03-14 |
| AR130417A1 (es) | 2024-12-04 |
| KR20250057022A (ko) | 2025-04-28 |
| US20240116932A1 (en) | 2024-04-11 |
| AU2023338199A1 (en) | 2025-03-20 |
| EP4584270A1 (en) | 2025-07-16 |
| CA3266872A1 (en) | 2024-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2716633T3 (en) | QUINAZOLINE DERIVATIVE AS A TYROSIN-KINASE INHIBITOR, PROCEDURE FOR PREPARING IT AND USING THEREOF | |
| RU2019101220A (ru) | Кристаллические формы соединения триазолопиримидина | |
| CN115850291B (zh) | 喜树碱衍生物及其用途 | |
| JP7153069B2 (ja) | ロルラチニブ遊離塩基水和物の結晶形態 | |
| IL319342A (en) | Co-crystals of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxyethoxy]pyrazolo[1,5-A]pyridin-6-yl]-5-methyl-triazol-1-yl]piperidine-1-caridine-1-caridine and nicotinamide | |
| CN102516263A (zh) | 一种螺三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用 | |
| RU2012144420A (ru) | Новые способы направленного воздействия на раковые стволовые клетки | |
| RU2007141198A (ru) | Кристаллическая форма малеата азенапина | |
| WO2023209692A1 (en) | Inhibitors of rock2 | |
| JP2024037713A5 (enExample) | ||
| EP1549647B1 (de) | Substituierte c-imidazo¬1,2-a|pyridin-3-yl-methylamine | |
| CN104860922A (zh) | 作为间变性淋巴瘤激酶抑制剂的嘧啶衍生物 | |
| CN108084177A (zh) | 一种小檗碱9-位吡唑衍生物及其制备和应用 | |
| CN114072412A (zh) | 三环化合物、药物组合物及其应用 | |
| CN105439913A (zh) | 一种吉马酮衍生物及其制备方法和应用 | |
| US10196344B2 (en) | Glaucocalyxin a derivative and preparation method and application thereof | |
| RU2019134064A (ru) | Кристаллическая натриевая соль 5-метил-(6s)-тетрагидрофолиевой кислоты | |
| US11111234B2 (en) | Salt of a quinazoline derivative-like tyrosine kinase inhibitor and crystal form thereof | |
| CN103588776A (zh) | 葱莲中具有抗肿瘤作用的化合物及其分离制备方法和应用 | |
| CN116554111B (zh) | 一种厄洛替尼共无定形物及其制备方法与应用 | |
| CN115650913B (zh) | 醌式喹啉类化合物及其制备方法和用途 | |
| CN114426541B (zh) | 氮杂芳基化合物及其用途 | |
| CN104876902A (zh) | 7-环己烷甲基-5-(2’-氨基)苯基白杨素及其制备方法和应用 | |
| CN112773812A (zh) | 新型喜树碱衍生物制备抗肿瘤药物的应用 | |
| WO2019141549A1 (en) | 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53 |